Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minim...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Richardson, Paul G., Siegel, David, Baz, Rachid, Kelley, Susan L., Munshi, Nikhil C., Laubach, Jacob, Sullivan, Daniel, Alsina, Melissa, Schlossman, Robert, Ghobrial, Irene M., Doss, Deborah, Loughney, Nora, McBride, Laura, Bilotti, Elizabeth, Anand, Palka, Nardelli, Lisa, Wear, Sandra, Larkins, Gail, Chen, Min, Zaki, Mohamad H., Jacques, Christian, Anderson, Kenneth C.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2013
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123324/
https://ncbi.nlm.nih.gov/pubmed/23243282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-450742
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker